The Wall Street Journal

Drug Prices Rise Despite Calls for Cuts

Even as government and private health plans push to restrain spending on medicines, the prices of brand name prescriptions are climbing rapidly, reaching the steepest rate of the decade last year.

How Bargain Lipitor Could Raise Health Costs

A war over Lipitor pricing could impact your pocketbook whether or not you take the best-selling cholesterol-lowering pill.

If Drug Copays Have You Down, Check For a Coupon

There are coupons or subsidy cards to reduce copays for about half of the top 100 brand name drugs sold in this country, according to a recent report from health analyst Richard Evans at Sector & Sovereign Research.

Lipitor Factory is One Pfizer Casualty

If you want to understand why Pfizer is closing eight manufacturing plants and laying off 6,000 workers over the next five years, its plant at Loughbeg in County Cork, Ireland, would be a good place to start.

Bloomberg

Richard Evans guides institutional investors through his Healthcare research at Bloomberg World Headquarters in May of this year.  The symposium was hosted by Bloomberg Tradebook and materials are available upon request.

Bloomberg

Evans thoughts on the President’s Healthcare Proposal

What’s Next for Health Care Companies?

Since November, one experienced industry analyst has been saying health care reform is “simply over.” What does he think now?

Prospects for Health Overhaul Dim After Massachusetts Vote

The Kennedy seat in the Senate is gone. With its loss, Democrats’ hopes for passing an overhaul of the nation’s health system have faded, too.

Bloomberg

Evans Says U.S. Health Bills Potentially Irreconcilable

Analyst Doubts Health Overhaul Can Pass

Arguing that the political winds are shifting away from the support necessary for an overhaul, one Wall Street analyst is now predicting Congress will not pass any significant health care legislation anytime soon.

Analyst: Insurers Needn’t Fear Public Option

In a report sent to investors earlier this week, a Wall Street analyst, Richard Evans, concludes that the health insurance industry should probably not worry much about the prospect of a government-run health plan — at least not as it now is taking shape in Congress.

Prescriptions: Contrarian View: The Proposed Fine for Going Without Insurance Is Too Low

Some have criticized the Baucus health care proposal as punitive because it would fine people who did not sign up for health insurance. But a Wall Street health care analyst says the fines are too low.